Hints and tips:
...The chief executive of Bristol-Myers Squibb described the US government’s support for waiver as “very concerning” during an interview at the FT US Pharma and Biotech Summit on Thursday....
...Consensus forecasts are much lower because Bristol-Myers Squibb and Merck & Co are around two years ahead of AstraZeneca in the development of monotherapy cancer treatments....
...Squibb....
International Edition